Vulnerability of mesostriatal dopaminergic neurons in Parkinson's disease

Frontiers in Neuroanatomy

Volumn , Issue OCT, 2010, Pages

  González Hernández, Tomás ^a,b   Cruz Muros, Ignacio ^a,b   Afonso Oramas, Domingo ^a   Salas Hernandez, Josmar ^a   Castro Hernandez, Javier ^a  

^a UNIVERSIDAD DE LA LAGUNA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

Author keywords

Aging; Differential vulnerability; Mesolimbic; Mitochondrion; Neurodegeneration; Nigrostriatal; Parkinson's disease; Proteostasis

Indexed keywords

DOPAMINE; DOPAMINE TRANSPORTER; GLUTAMIC ACID;

ACTION POTENTIAL; AGING; ARTICLE; CELL ACTIVITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; EXCITOTOXICITY; GENE MUTATION; HUMAN; MESENCEPHALON; NERVE CELL DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; PROTEIN HOMEOSTASIS; RISK ASSESSMENT; RISK FACTOR;

EID: 80052813660     PISSN: 16625129     EISSN: None     Source Type: Journal    
DOI: 10.3389/fnana.2010.00140     Document Type: Article

References (253)

1. Abou-Sleiman, P. M., Healy, D. G., Quinn, N., Lees, A. J., and Wood, N. W. (2003). The role of pathogenic DJ-1 mutations in Parkinson's disease. Ann. Neurol. 54, 283-286.
2. Afonso-Oramas, D., Cruz-Muros, I., Alvarez de la Rosa D., Abreu, P., Giraldez, T., Castro-Hernandez, J., Salas-Hernandez, J., Lanciego, J. L., Rodriguez, M., and Gonzalez-Hernandez, T. (2009). Dopamine transporter glycosylation correlates with the vulnerability of midbrain dopaminergic cells in Parkinson's disease. Neurobiol. Dis. 36, 494-508.
3. Airaksinen, M. S., Thoenen, H., and Meyer, M. (1997). Vulnerability of midbrain dopaminergic neurons in calbindin-D28k-deficient mice: lack of evidence for a neuroprotective role of endogenous calbindin in MPTP-treated and weaver mice. Eur. J. Neurosci. 9, 120-127.
4. Alnemri, E. S. (2007). HtrA2 and Parkinson's disease: think PINK? Nat. Cell Biol. 9, 1227-1229.
5. Ashley, A. K., Hanneman, W. H., Katoh, T., Moreno, J. A., Pollack, A., Tjalkens, R. B., and Legare, M. E. (2009). Analysis of targeted mutation in DJ-1 on cellular function in primary astrocytes. Toxicol. Lett. 184, 186-191.
6. Baker, D. A., Xi, Z. X., Shen, H., Swanson, C. J., and Kalivas, P. W. (2002). The origin and neuronal function of in vivo nonsynaptic glutamate. J. Neurosci. 22, 9134-9141.
7. Banati, R. B., Daniel, S. E., and Blunt, S. B. (1998). Glial pathology but absence of apoptotic nigral neurons in longstanding Parkinson's disease. Mov. Disord. 13, 221-227.
8. Barzilai, A., Melalmed, E., and Shirvan, A. (2001). Is there a rationale for neuroprotection against dopamine toxicity in Parkinson's disease. Cell. Mol. Neurobiol. 21, 215-235.
9. Bas, J., Calopa, M., Mestre, M., Mollevi, D. G., Cutillas, B., Ambrosio, S., and Buendia, E. (2001). Lymphocyte populations in Parkinson's disease and in rat models of parkinsonism. J. Neuroimmunol. 113, 146-152.
10. Ben-Shachar, D., Riederer, P., and Youdim, M. B. (1991). Iron-melanin interaction and lipid peroxidation: implications for Parkinson's disease. J. Neurochem. 57, 1609-1614.
11. Benazzouz, A., Breit, S., Koudsie, A., Pollak, P., Krack, P., and Benabid, A. L. (2002). Intraoperative microrecordings of the subthalamic nucleus in Parkinson's disease. Mov. Disord. 17 (Suppl. 3), S145-S149.
12. Bender, A., Krishnan, K. J., Morris, C. M., Taylor, G. A., Reeve, A. K., Perry, R. H., Jaros, E., Hersheson, J. S., Betts, J., Klopstock, T., Taylor, R. W., and Turnbull, D. M. (2006). High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat. Genet. 38, 515-517.
13. Bennett, M. C. (2005). The role of alphasynuclein in neurodegenerative diseases. Pharmacol. Ther. 105, 311-331.
14. Bennett, M. C., Bishop, J. F., Leng, Y., Chock, P. B., Chase, T. N., and Mouradian, M. M. (1999). Degradation of alphasynuclein by proteasome. J. Biol. Chem. 274, 33855-33858.
15. Bergman, H., Wichmann, T., Karmon, B., and DeLong, M. R. (1994). The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism. J. Neurophysiol. 72, 507-520.
16. Berman, S. B., and Hasting, T. G. (1999). Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson's disease. J. Neurochem. 73, 1127-1137.
17. Berridge, M. J. (2002). The endoplasmic reticulum: a multifunctional signaling organelle. Cell Calcium 32, 235-249.
18. Betarbet, R., Sherer, T. B., MacKenzie, G., Garcia-Osuna, M., Panov, A. V., and Greenamyre, J. T. (2000). Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 3, 1301-1306.
19. Bezard, E., Boraud, T., Bioulac, B., and Gross, C. E. (1999a). Involvement of the subthalamic nucleus in glutamatergic compensatory mechanisms. Eur. J. Neurosci. 11, 2167-2170.
20. Bezard, E., Gross, C. E., Fournier, M. C., Dovero, S., Bloch, B., and Jaber, M. (1999b). Absence of MPTP-induced neuronal death in mice lacking the dopamine transporter. Exp. Neurol. 155, 268-273.
21. Biskup, S., Moore, D. J., Celsi, F., Higashi, S., West, A. B., Andrabi, S. A., Kurkinen, K., Yu, S. W., Savitt, J. M., Waldvogel, H. J., Faull, R. L., Emson, P. C., Torp, R., Ottersen, O. P., Dawson, T. M., and Dawson, V. L. (2006). Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann. Neurol. 60, 557-569.
22. Blum, D., Torch, S., Lambeng, N., Nissou, M., Benabid, A. L., Sadoul, R., and Verna, J. M. (2001). Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog. Neurobiol. 65, 135-172.
23. Blum-Degen, D., Muller, T., Kuhn, W., Gerlach, M., Przuntek, H., and Riederer, P. (1995). Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci. Lett. 202, 17-20.
24. Boka, G., Anglade, P., Wallach, D., Javoy-Agid, F., Agid, Y., and Hirsch, E. C. (1994). Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease. Neurosci. Lett. 172, 151-154.
25. Bonifati, V., Rizzu, P., van Baren, M. J., Schaap, O., Breedveld, G. J., Krieger, E., Dekker, M. C., Squitieri, F., Ibanez, P., Joosse, M., van Dongen, J. W., Vanacore, N., van Swieten, J. C., Brice, A., Meco, G., van Duijn, C. M., Oostra, B. A., and Heutink, P. (2003). Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299, 256-259.
26. Borland, M. K., Mohanakumar, K. P., Rubinstein, J. D., Keeney, P. M., Xie, J., Capaldi, R., Dunham, L. D., Trimmer, P. A., and Bennett, J. P. Jr. (2009). Relationships among molecular genetic and respiratory properties of Parkinson's disease cybrid cells show similarities to Parkinson's brain tissues. Biochim. Biophys. Acta 1792, 68-74.
27. Bove, J., Prou, D., Perier, C., and Przedborski, S. (2005). Toxin-induced models of Parkinson's disease. NeuroRx 2, 484-494.
28. Braak, H., Del Tredici, K., Rub, U., de Vos, R. A., Jansen Steur, E. N., and Braak, E. (2003). Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24, 197-211.
29. Burke, R. E., Dauer, W. T., and Vonsattel, J. P. (2008). A critical evaluation of the Braak staging scheme for Parkinson's disease. Ann. Neurol. 64, 485-491.
30. Burnashev, N., Monyer, H., Seeburg, P. H., and Sakmann, B. (1992). Divalent ion permeability of AMPA receptor channels is dominated by the edited form of a single subunit. Neuron 8, 189-198.
31. Cabello, C. R., Thune, J. J., Pakkenberg, H., and Pakkenberg, B. (2002). Ageing of substantia nigra in humans: cell loss may be compensated by hypertrophy. Neuropathol. Appl. Neurobiol. 28, 283-291.
32. Canet-Aviles, R. M., Wilson, M. A., Miller, D. W., Ahmad, R., McLendon, C., Bandyopadhyay, S., Baptista, M. J., Ringe, D., Petsko, G. A., and Cookson, M. R. (2004). The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proc. Natl. Acad. Sci. U.S.A. 101, 9103-9108.
33. Cannon, J. R., Tapias, V., Na, H. M., Honick, A. S., Drolet, R. E., and Greenamyre, J. T. (2009). A highly reproducible rotenone model of Parkinson's disease. Neurobiol. Dis. 34, 279-290.
34. Cass, W. A., Gerhardt, G. A., Mayfield, R. D., Curella, P., and Zahniser, N. R. (1992). Differences in dopamine clearance and diffusion in rat striatum and nucleus accumbens following systemic cocaine administration. J. Neurochem. 59, 259-266.
35. Caudle, W. M., Richardson, J. R., Wang, M. Z., Taylor, T. N., Guillot, T. S., McCormack, A. L., Colebrooke, R. E., Di Monte, D. A., Emson, P. C., and Miller, G. W. (2007). Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration. J. Neurosci. 27, 8138-8148.
36. Cavelier, P., and Attwell, D. (2005). Tonic release of glutamate by a DIDS-sensitive mechanism in rat hippocampal slices. J. Physiol. 564, 397-410.
37. Celsi, F., Pizzo, P., Brini, M., Leo, S., Fotino, C., Pinton, P., and Rizzuto, R. (2009). Mitochondria, calcium and cell death: a deadly triad in neurodegeneration. Biochim. Biophys. Acta 1787, 335-344.
38. Cerruti, C., Walther, D. M., Kuhar, M. J., and Uhl, G. R. (1993). Dopamine transporter mRNA expression is intense in rat midbrain neurons and modest outside midbrain. Brain Res. Mol. Brain Res. 18, 181-186.
39. Chan, C. S., Gertler, T. S., and Surmeier, D. J. (2009). Calcium homeostasis, selective vulnerability and Parkinson's disease. Trends Neurosci. 32, 249-256.
40. Chan, C. S., Guzman, J. N., Ilijic, E., Mercer, J. N., Rick, C., Tkatch, T., Meredith, G. E., and Surmeier, D. J. (2007). 'Rejuvenation' protects neurons in mouse models of Parkinson's disease. Nature 447, 1081-1086.
41. Charara, A., Smith, Y., and Parent, A. (1996). Glutamatergic inputs from the pedunculopontine nucleus to midbrain dopaminergic neurons in primates: phaseolus vulgarisleucoagglutinin anterograde labeling combined with postembedding glutamate and GABA immunohistochemistry. J. Comp. Neurol. 364, 254-266.
42. 2+ diffusion. J. Neurosci. 26, 12127-12136.
43. Chung, C. Y., Seo, H., Sonntag, K. C., Brooks, A., Lin, L., and Isacson, O. (2005). Cell type-specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection. Hum. Mol. Genet. 14, 1709-1725.
44. Cicchetti, F., Drouin-Ouellet, J., and Gross, R. E. (2009). Environmental toxins and Parkinson's disease: what have we learned from pesticide-induced animal models? Trends Pharmacol. Sci. 30, 475-483.
45. Collier, T. J., Lipton, J., Daley, B. F., Palfi, S., Chu, Y., Sortwell, C., Bakay, R. A., Sladek, J. R., Jr., and Kordower, J. H. (2007). Aging-related changes in the nigrostriatal dopamine system and the response to MPTP in nonhuman primates: diminished compensatory mechanisms as a prelude to parkinsonism. Neurobiol. Dis. 26, 56-65.
46. Conn, P. J., and Pin, J. P. (1997). Pharmacology and functions of metabotropic glutamate receptors. Annu. Rev. Pharmacol. Toxicol. 37, 205-237.
47. Conway, K. A., Lee, S. J., Rochet, J. C., Ding, T. T., Williamson, R. E., and Lansbury, P. T. Jr. (2000). Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc. Natl. Acad. Sci. U.S.A. 97, 571-576.
48. Cruz-Muros, I., Afonso-Oramas, D., Abreu, P., Barroso-Chinea, P., Rodriguez, M., Gonzalez, M. C., and Hernandez, T. G. (2007). Aging of the rat mesostriatal system: differences between the nigrostriatal and the mesolimbic compartments. Exp. Neurol. 204, 147-161.
49. Cruz-Muros, I., Afonso-Oramas, D., Abreu, P., Rodriguez, M., Gonzalez, M. C., and Gonzalez-Hernandez, T. (2008). Deglycosylation and subcellular redistribution of VMAT2 in the mesostriatal system during normal aging. Neurobiol. Aging 29, 1702-1711.
50. Cuervo, A. M., Stefanis, L., Fredenburg, R., Lansbury, P. T., and Sulzer, D. (2004). Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 305, 1292-1295.
51. + binds to neuromelanin. Science 231, 987-989.
52. Damier, P., Hirsch, E. C., Agid, Y., and Graybiel, A. M. (1999). The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 122(Pt 8), 1437-1448.
53. Darios, F., Corti, O., Lucking, C. B., Hampe, C., Muriel, M. P., Abbas, N., Gu, W. J., Hirsch, E. C., Rooney, T., Ruberg, M., and Brice, A. (2003). Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria-dependent cell death. Hum. Mol. Genet. 12, 517-526.
54. Dauer, W., and Przedborski, S. (2003). Parkinson's disease: mechanisms and models. Neuron 39, 889-909.
55. de Lau, L. M., and Breteler, M. M. (2006). Epidemiology of Parkinson's disease. Lancet Neurol. 5, 525-535.
56. Dervan, A. G., Meshul, C. K., Beales, M., McBean, G. J., Moore, C., Totterdell, S., Snyder, A. K., and Meredith, G. E. (2004). Astroglial plasticity and glutamate function in a chronic mouse model of Parkinson's disease. Exp. Neurol. 190, 145-156.
57. Devi, L., Raghavendran, V., Prabhu, B. M., Avadhani, N. G., and Anandatheerthavarada, H. K. (2008). Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J. Biol. Chem. 283, 9089-9100.
58. Dhillon, A. S., Tarbutton, G. L., Levin, J. L., Plotkin, G. M., Lowry, L. K., Nalbone, J. T., and Shepherd, S. (2008). Pesticide/environmental exposures and Parkinson's disease in East Texas. J. Agromedicine 13, 37-48.
59. Di Fonzo, A., Rohe, C. F., Ferreira, J., Chien, H. F., Vacca, L., Stocchi, F., Guedes, L., Fabrizio, E., Manfredi, M., Vanacore, N., Goldwurm, S., Breedveld, G., Sampaio, C., Meco, G., Barbosa, E., Oostra, B. A., and Bonifati, V. (2005). A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease. Lancet 365, 412-415.
60. Di Matteo, V., Pierucci, M., Di Giovanni, G., Di Santo, A., Poggi, A., Benigno, A., and Esposito, E. (2006). Aspirin protects striatal dopaminergic neurons from neurotoxin-induced degeneration: an in vivo microdialysis study. Brain Res. 1095, 167-177.
61. Di Monte, D., Jewell, S. A., Ekstrom, G., Sandy, M. S., and Smith, M. T. (1986a). 1-Methyl-4-phenyl-1,2,3,6t{stroke}etrahydropyridine (MPTP) and 1-methyl-4-phenylpyridine (MPP+) cause rapid ATP depletion in isolated hepatocytes. Biochem. Biophys. Res. Commun. 137, 310-315.
62. Di Monte, D., Sandy, M. S., Ekstrom, G., and Smith, M. T. (1986b). Comparative studies on the mechanisms of paraquat and 1-methyl-4-phenylpyridine (MPP+) cytotoxicity. Biochem. Biophys. Res. Commun. 137, 303-309.
63. Enochs, W. S., Sarna, T., Zecca, L., Riley, P. A., and Swartz, H. M. (1994). The roles of neuromelanin, binding of metal ions, and oxidative cytotoxicity in the pathogenesis of Parkinson's disease: a hypothesis. J. Neural. Transm. Park. Dis. Dement. Sect. 7, 83-100.
64. Fasano, M., Bergamasco, B., and Lopiano, L. (2006). Modifications of ironneuromelanin system in Parkinson's disease. J. Neurochem. 96, 909-916.
65. Fearnley, J. M., and Lees, A. J. (1991). Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 114 (Pt 5), 2283-2301.
66. Firestone, J. A., Smith-Weller, T., Franklin, G., Swanson, P., Longstreth, W. T. Jr., and Checkoway, H. (2005). Pesticides and risk of Parkinson disease: a population-based case-control study. Arch. Neurol. 62, 91-95.
67. Foix, C., and Nicolesco, J. (1925). Anatomie cérébrale. Les noyaux gris centraux et la región Mésencéphalosous-optique., Suivi d'un apéndice sur l'anatomie pathologique de la maladie de Parkinson. Paris: Masson et Cie, pp. 508-538.
68. Forno, L. S. (1996). Neuropathology of Parkinson's disease. J. Neuropathol. Exp. Neurol. 55, 259-272.
69. Fornsted, B., Rosengren, E., and Carlsson, A. (1986). Occurrence and distribution of 5-S-cysteinyl derivates of dopamine, dopa and dopac in brains of eight mammalian species. Neuropharmacology 25, 451-454.
70. Forster, G. L., and Blaha, C. D. (2003). Pedunculopontine tegmental stimulation evokes striatal dopamine efflux by activation of acetylcholine and glutamate receptors in the midbrain and pons of the rat. Eur. J. Neurosci. 17, 751-762.
71. Fredenburg, R. A., Rospigliosi, C., Meray, R. K., Kessler, J. C., Lashuel, H. A., Eliezer, D., and Lansbury, P. T. Jr. (2007). The impact of the E46K mutation on the properties of alpha-synuclein in its monomeric and oligomeric states. Biochemistry 46, 7107-7118.
72. Gainetdinov, R. R., Fumagalli, F., Jones, S. R., and Caron, M. G. (1997). Dopamine transporter is required for in vivo MPTP neurotoxicity: evidence from mice lacking the transporter. J. Neurochem. 69, 1322-1325.
73. Galluzzi, L., Blomgren, K., and Kroemer, G. (2009). Mitochondrial membrane permeabilization in neuronal injury. Nat. Rev. Neurosci. 10, 481-494.
74. Garcia, L., D'Alessandro, G., Fernagut, P. O., Bioulac, B., and Hammond, C. (2005). Impact of high-frequency stimulation parameters on the pattern of discharge of subthalamic neurons. J. Neurophysiol. 94, 3662-3669.
75. Gautier, C. A., Kitada, T., and Shen, J. (2008). Loss of PINK1 causes mitochondrial functional defects and increased sensitivity to oxidative stress. Proc. Natl. Acad. Sci. U.S.A. 105, 11364-11369.
76. 2+ permeability of AMPA receptors in principal neurons and interneurons in rat CNS. Neuron 15, 193-204.
77. Gerfen, C. R., Baimbridge, K. G., and Miller, J. J. (1985). The neostriatal mosaic: compartmental distribution of calcium-binding protein and parvalbumin in the basal ganglia of the rat and monkey. Proc. Natl. Acad. Sci. U.S.A. 82, 8780-8784.
78. Gerfen, C. R., Herkenham, M., and Thibault, J. (1987). The neostriatal mosaic: II. Patch-and matrix-directed mesostriatal dopaminergic and nondopaminergic systems. J. Neurosci. 7, 3915-3934.
79. Gerhardt, G. A., Cass, W. A., Yi, A., Zhang, Z., and Gash, D. M. (2002). Changes in somatodendritic but not terminal dopamine regulation in aged rhesus monkeys. J. Neurochem. 80, 168-177.
80. German, D. C., Manaye, K., Smith, W. K., Woodward, D. J., and Saper, C. B. (1989). Midbrain dopaminergic cell loss in Parkinson's disease: computer visualization. Ann. Neurol. 26, 507-514.
81. German, D. C., Manaye, K. F., Sonsalla, P. K., and Brooks, B. A. (1992). Midbrain dopaminergic cell loss in Parkinson's disease and MPTP-induced parkinsonism: sparing of calbindin-D28kcontaining cells. Ann. N.Y. Acad. Sci. 648, 42-62.
82. Giasson, B. I., Covy, J. P., Bonini, N. M., Hurtig, H. I., Farrer, M. J., Trojanowski, J. Q., and Van Deerlin, V. M. (2006). Biochemical and pathological characterization of Lrrk2. Ann. Neurol. 59, 315-322.
83. Gibb, W. (1992). Melanin, tyrosine hydroxylase, calbindin and substance P in the human midbrain and substantia nigra in relation to nigrastriatal projections and differential neuron susceptibility in Parkinson's disease. Brain Res. 581, 283-291.
84. Gibb, W. R., and Lees, A. J. (1988). A comparison of clinical and pathological features of young-and old-onset Parkinson's disease. Neurology 38, 1402-1406.
85. Giros, B., and Caron, M. G. (1993). Molecular characterization of the dopamine transporter. Trends Pharmacol. Sci. 14, 43-49.
86. Gloeckner, C. J., Kinkl, N., Schumacher, A., Braun, R. J., O'Neill, E., Meitinger, T., Kolch, W., Prokisch, H., and Ueffing, M. (2006). The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum. Mol. Genet. 15, 223-232.
87. Goldberg, M. S., Pisani, A., Haburcak, M., Vortherms, T. A., Kitada, T., Costa, C., Tong, Y., Martella, G., Tscherter, A., Martins, A., Bernardi, G., Roth, B. L., Pothos, E. N., Calabresi, P., and Shen, J. (2005). Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial Parkinsonism-linked gene DJ-1. Neuron 45, 489-496.
88. Gonzalez-Hernandez, T., Afonso-Oramas, D., and Cruz-Muros, I. (2009). Phenotype, compartmental organization and differential vulnerability of nigral dopaminergic neurons. J. Neural. Transm. Suppl. 21-37.
89. Gonzalez-Hernandez, T., Barroso-Chinea, P., De La Cruz Muros I., Del Mar Perez-Delgado M., and Rodriguez, M. (2004). Expression of dopamine and vesicular monoamine transporters and differential vulnerability of mesostriatal dopaminergic neurons. J. Comp. Neurol. 479, 198-215.
90. Greene, J. G., Dingledine, R., and Greenamyre, J. T. (2005). Gene expression profiling of rat midbrain dopamine neurons: implications for selective vulnerability in parkinsonism. Neurobiol. Dis. 18, 19-31.
91. Greffard, S., Verny, M., Bonnet, A. M., Beinis, J. Y., Gallinari, C., Meaume, S., Piette, F., Hauw, J. J., and Duyckaerts, C. (2006). Motor score of the unified Parkinson disease rating scale as a good predictor of Lewy body-associated neuronal loss in the substantia nigra. Arch. Neurol. 63, 584-588.
92. Haas, R. H., Nasirian, F., Nakano, K., Ward, D., Pay, M., Hill, R., and Shults, C. W. (1995). Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease. Ann. Neurol. 37, 714-722.
93. Haber, S. N., Ryoo, H., Cox, C., and Lu, W. (1995). Subsets of midbrain dopaminergic neurons in monkeys are distinguished by different levels of mRNA for the dopamine transporter: comparison with the mRNA for the D2 receptor, tyrosine hydroxylase and calbindin immunoreactivity. J. Comp. Neurol. 362, 400-410.
94. Harman, D. (1956). Aging: a theory based on free radical and radiation chemistry. J. Gerontol. 11, 298-300.
95. Harrower, T. P., Michell, A. W., and Barker, R. A. (2005). Lewy bodies in Parkinson's disease: protectors or perpetrators? Exp. Neurol. 195, 1-6.
96. Hassler, R. (1938). Zur pathologie der paralysis agitans und des postencephalitschen Parkinsonismus. J. Psychol. Neurol. 48, 387-476.
97. Hasting, T. G. (1995). Enzymatic oxidation of dopamine: the role of prostaglandin H synthase. J. Neurochem. 64, 919-924.
98. Haycock, J. W., Becker, L., Ang, L., Furukawa, Y., Hornykiewicz, O., and Kish, S. J. (2003). Marked disparity between age-related changes in dopamine and other presynaptic dopaminergic markers in human striatum. J. Neurochem. 87, 574-585.
99. Hindle, J. V. (2010). Ageing, neurodegeneration and Parkinson's disease. Age Ageing 39, 156-161.
100. Hirsch, E., Graybiel, A., and Agid, Y. (1988). Melanized dopamine neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 334, 345-348.
101. Hirsch, E. C., and Hunot, S. (2009). Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol. 8, 382-397.
102. Hisanaga, K., Asagi, M., Itoyama, Y., and Iwasaki, Y. (2001). Increase in peripheral CD4 bright+ CD8 +dull T cells in Parkinson disease. Arch. Neurol. 58, 1580-1583.
103. Hoglinger, G. U., Feger, J., Prigent, A., Michel, P. P., Parain, K., Champy, P., Ruberg, M., Oertel, W. H., and Hirsch, E. C. (2003). Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats. J. Neurochem. 84, 491-502.
104. Hollmann, M., and Heinemann, S. (1994). Cloned glutamate receptors. Annu. Rev. Neurosci. 17, 31-108.
105. Horn, A. S. (1990). Dopamine uptake: a review of progress in the last decade. Prog. Neurobiol. 34, 387-400.
106. Hornykiewicz, O. (2006). The discovery of dopamine deficiency in the parkinsonian brain. J. Neural Transm. Suppl. 70, 9-15.
107. Hosoi, T., and Ozawa, K. (2009). Endoplasmic reticulum stress in disease: mechanisms and therapeutic opportunities. Clin. Sci. (Lond) 118, 19-29.
108. Hsu, L. J., Sagara, Y., Arroyo, A., Rockenstein, E., Sisk, A., Mallory, M., Wong, J., Takenouchi, T., Hashimoto, M., and Masliah, E. (2000). alphasynuclein promotes mitochondrial deficit and oxidative stress. Am. J. Pathol. 157, 401-410.
109. Hunot, S., Boissiere, F., Faucheux, B., Brugg, B., Mouatt-Prigent, A., Agid, Y., and Hirsch, E. C. (1996). Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Neuroscience 72, 355-363.
110. Hurd, Y. L., Pristupa, Z. B., Herman, M. M., Niznik, H. B., and Kleinman, J. E. (1994). The dopamine transporter and dopamine D2 receptor messenger RNAs are differentially expressed in limbicand motor-related subpopulations of human mesencephalic neurons. Neuroscience 63, 357-362.
111. Hurley, S. D., O'Banion, M. K., Song, D. D., Arana, F. S., Olschowka, J. A., and Haber, S. N. (2003). Microglial response is poorly correlated with neurodegeneration following chronic, low-dose MPTP administration in monkeys. Exp. Neurol. 184, 659-668.
112. Iaccarino, C., Crosio, C., Vitale, C., Sanna, G., Carri, M. T., and Barone, P. (2007). Apoptotic mechanisms in mutant LRRK2-mediated cell death. Hum. Mol. Genet. 16, 1319-1326.
113. Imai, Y., Soda, M., Inoue, H., Hattori, N., Mizuno, Y., and Takahashi, R. (2001). An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin. Cell 105, 891-902.
114. Imamura, K., Hishikawa, N., Sawada, M., Nagatsu, T., Yoshida, M., and Hashizume, Y. (2003). Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains. Acta Neuropathol. 106, 518-526.
115. Iribe, Y., Moore, K., Pang, K. C., and Tepper, J. M. (1999). Subthalamic stimulationinduced synaptic responses in substantia nigra pars compacta dopaminergic neurons in vitro. J. Neurophysiol. 82, 925-933.
116. Irwin, I., DeLanney, L. E., McNeill, T., Chan, P., Forno, L. S., Murphy, G. M., Jr., Di Monte, D. A., Sandy, M. S., and Langston, J. W. (1994). Aging and the nigrostriatal dopamine system: a non-human primate study. Neurodegeneration 3, 251-265.
117. Jellinger, K. A. (2009). Recent advances in our understanding of neurodegeneration. J. Neural. Transm. 116, 1111-1162.
118. Jenner, P. (2003). Oxidative stress in Parkinson's disease. Ann. Neurol. 53 (Suppl. 3), S26-S36; discussion S28-S36.
119. Joglar, B., Rodriguez-Pallares, J., Rodriguez-Perez, A. I., Rey, P., Guerra, M. J., and Labandeira-Garcia J. L. (2009). The inflammatory response in the MPTP model of Parkinson's disease is mediated by brain angiotensin: relevance to progression of the disease. J. Neurochem. 109, 656-669.
120. Jonsson, G. (1971). Quantitation of fluorescence of biogenic monoamines. Prog. Histochem. Cytochem. 2, 244-299.
121. Keeney, P. M., Xie, J., Capaldi, R. A., and Bennett, J. P. Jr. (2006). Parkinson's disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled. J. Neurosci. 26, 5256-5264.
122. Kim, R. H., Smith, P. D., Aleyasin, H., Hayley, S., Mount, M. P., Pownall, S., Wakeham, A., You-Ten, A. J., Kalia, S. K., Horne, P., Westaway, D., Lozano, A. M., Anisman, H., Park, D. S., and Mak, T. W. (2005). Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress. Proc. Natl. Acad. Sci. U.S.A. 102, 5215-5220.
123. Kim, Y., Park, J., Kim, S., Song, S., Kwon, S. K., Lee, S. H., Kitada, T., Kim, J. M., and Chung, J. (2008). PINK1 controls mitochondrial localization of Parkin through direct phosphorylation. Biochem. Biophys. Res. Commun. 377, 975-980.
124. Kish, S. J., Shannak, K., Rajput, A., Deck, J. H., and Hornykiewicz, O. (1992). Aging produces a specific pattern of striatal dopamine loss: implications for the etiology of idiopathic Parkinson's disease. J. Neurochem. 58, 642-648.
125. Kita, H., and Kitai, S. T. (1987). Efferent projections of the subthalamic nucleus in the rat: light and electron microscopic analysis with the PHA-L method. J. Comp. Neurol. 260, 435-452.
126. Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., and Shimizu, N. (1998). Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392, 605-608.
127. Knott, C., Stern, G., and Wilkin, G. P. (2000). Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2. Mol. Cell. Neurosci. 16, 724-739.
128. Kopin, I. J. (1992). Features of the dopaminergic neurotoxin MPTP. Ann. N. Y. Acad. Sci. 648, 96-104.
129. Kraytsberg, Y., Kudryavtseva, E., McKee, A. C., Geula, C., Kowall, N. W., and Khrapko, K. (2006). Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons. Nat. Genet. 38, 518-520.
130. Krige, D., Carroll, M. T., Cooper, J. M., Marsden, C. D., and Schapira, A. H. (1992). Platelet mitochondrial function in Parkinson's disease. The Royal Kings and Queens Parkinson Disease Research Group. Ann. Neurol. 32, 782-788.
131. Kroemer, G., and Blomgren, K. (2007). Mitochondrial cell death control in familial Parkinson disease. PLoS Biol. 5, e206. doi: 10.1371/journal.pbio.0050206.
132. Kubis, N., Faucheux, B. A., Ransmayr, G., Damier, P., Duyckaerts, C., Henin, D., Forette, B., Le Charpentier, Y., Hauw, J. J., Agid, Y., and Hirsch, E. C. (2000). Preservation of midbrain catecholaminergic neurons in very old human subjects. Brain 123 (Pt 2), 366-373.
133. Kuhn, D. M., Francescutti-Verbeem, D. M., and Thomas, D. M. (2006). Dopamine quinones activate microglia and induce a neurotoxic gene expression profile: relationship to methamphetamine-induced nerve ending damage. Ann. N.Y. Acad. Sci. 1074, 31-41.
134. Kurkowska-Jastrzebska, I., Babiuch, M., Joniec, I., Przybylkowski, A., Czlonkowski, A., and Czlonkowska, A. (2002). Indomethacin protects against neurodegeneration caused by MPTP intoxication in mice. Int. Immunopharmacol. 2, 1213-1218.
135. Kuroda, Y., Mitsui, T., Kunishige, M., and Matsumoto, T. (2006). Parkin affects mitochondrial function and apoptosis in neuronal and myogenic cells. Biochem. Biophys. Res. Commun. 348, 787-793.
136. LaFerla, F. M. (2002). Calcium dyshomeostasis and intracellular signalling in Alzheimer's disease. Nat. Rev. Neurosci. 3, 862-872.
137. Langston, J. W., Ballard, P., Tetrud, J. W., and Irwin, I. (1983). Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219, 979-980.
138. Lapointe, N., St-Hilaire, M., Martinoli, M. G., Blanchet, J., Gould, P., Rouillard, C., and Cicchetti, F. (2004). Rotenone induces non-specific central nervous system and systemic toxicity. FASEB J. 18, 717-719.
139. Lashuel, H. A., Petre, B. M., Wall, J., Simon, M., Nowak, R. J., Walz, T., and Lansbury, P. T. Jr. (2002). Alphasynuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J. Mol. Biol. 322, 1089-1102.
140. LaVoie, M. J., Ostaszewski, B. L., Weihofen, A., Schlossmacher, M. G., and Selkoe, D. J. (2005). Dopamine covalently modifies and functionally inactivates parkin. Nat. Med. 11, 1214-1221.
141. Lee, C. R., and Tepper, J. M. (2009). Basal ganglia control of substantia nigra dopaminergic neurons. J. Neural. Transm. Suppl. 71-90.
142. Lee, S. J., Kim, S. J., Kim, I. K., Ko, J., Jeong, C. S., Kim, G. H., Park, C., Kang, S. O., Suh, P. G., Lee, H. S., and Cha, S. S. (2003). Crystal structures of human DJ-1 and Escherichia coli Hsp31, which share an evolutionarily conserved domain. J. Biol. Chem. 278, 44552-44559.
143. Leroy, E., Boyer, R., Auburger, G., Leube, B., Ulm, G., Mezey, E., Harta, G., Brownstein, M. J., Jonnalagada, S., Chernova, T., Dehejia, A., Lavedan, C., Gasser, T., Steinbach, P. J., Wilkinson, K. D., and Polymeropoulos, M. H. (1998). The ubiquitin pathway in Parkinson's disease. Nature 395, 451-452.
144. Liang, C. L., Sinton, C. M., and German, D. C. (1996). Midbrain dopaminergic neurons in the mouse: co-localization with Calbindin-D28K and calretinin. Neuroscience 75, 523-533.
145. Liberatore, G. T., Jackson-Lewis, V., Vukosavic, S., Mandir, A. S., Vila, M., McAuliffe, W. G., Dawson, V. L., Dawson, T. M., and Przedborski, S. (1999). Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat. Med. 5, 1403-1409.
146. Limousin, P., Krack, P., Pollak, P., Benazzouz, A., Ardouin, C., Hoffmann, D., and Benabid, A. L. (1998). Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. N. Engl. J. Med. 339, 1105-1111.
147. Lindquist, N. G., Larsson, B. S., and Lydén-Sokolowski, A. (1988). Autoradiography of [14C] paraquat or [14C] diquat in frogs and mice: accumulation in neuromelanin. Neurosci. Lett. 93, 1-6.
148. Liou, H. H., Tsai, M. C., Chen, C. J., Jeng, J. S., Chang, Y. C., Chen, S. Y., and Chen, R. C. (1997). Environmental risk factors and Parkinson's disease: a casecontrol study in Taiwan. Neurology 48, 1583-1588.
149. Lippa, C. F., Duda, J. E., Grossman, M., Hurtig, H. I., Aarsland, D., Boeve, B. F., Brooks, D. J., Dickson, D. W., Dubois, B., Emre, M., Fahn, S., Farmer, J. M., Galasko, D., Galvin, J. E., Goetz, C. G., Growdon, J. H., Gwinn-Hardy, K. A., Hardy, J., Heutink, P., Iwatsubo, T., Kosaka, K., Lee, V. M., Leverenz, J. B., Masliah, E., McKeith, I. G., Nussbaum, R. L., Olanow, C. W., Ravina, B. M., Singleton, A. B., Tanner, C. M., Trojanowski, J. Q., and Wszolek, Z. K. (2007). DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology 68, 812-819.
150. Lohmann, E., Periquet, M., Bonifati, V., Wood, N. W., De Michele, G., Bonnet, A. M., Fraix, V., Broussolle, E., Horstink, M. W., Vidailhet, M., Verpillat, P., Gasser, T., Nicholl, D., Teive, H., Raskin, S., Rascol, O., Destee, A., Ruberg, M., Gasparini, F., Meco, G., Agid, Y., Durr, A., and Brice, A. (2003). How much phenotypic variation can be attributed to parkin genotype? Ann. Neurol. 54, 176-185.
151. Mak, S. K., McCormack, A. L., Manning-Bog, A. B., Cuervo, A. M., and Di Monte, D. A. (2010). Lysosomal degradation of alpha-synuclein in vivo. J. Biol. Chem. 285, 13621-13629.
152. Mann, D., and Yates, P. (1983). Possible role of neuromelanin in the pathogenesis of Parkinson's disease. Mech. Ageing Dev. 21, 193-203.
153. Manning-Bog, A. B., McCormack, A. L., Purisai, M. G., Bolin, L. M., and Di Monte, D. A. (2003). Alpha-synuclein overexpression protects against paraquat-induced neurodegeneration. J. Neurosci. 23, 3095-3099.
154. Marshall, J. F., O'Dell, S. J., Navarrete, R., and Rosenstein, A. J. (1990). Dopamine high-affinity transport site topography in rat brain: major differences between dorsal and ventral striatum. Neuroscience 37, 11-21.
155. Martin, L. J., Pan, Y., Price, A. C., Sterling, W., Copeland, N. G., Jenkins, N. A., Price, D. L., and Lee, M. K. (2006). Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. J. Neurosci. 26, 41-50.
156. McCormack, A. L., Di Monte, D. A., Delfani, K., Irwin, I., DeLanney, L. E., Langston, W. J., and Janson, A. M. (2004). Aging of the nigrostriatal system in the squirrel monkey. J. Comp. Neurol. 471, 387-395.
157. McCormack, A. L., Thiruchelvam, M., Manning-Bog, A. B., Thiffault, C., Langston, J. W., Cory-Slechta, D. A., and Di Monte, D. A. (2002). Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiol. Dis. 10, 119-127.
158. McCormack, J. G., Halestrap, A. P., and Denton, R. M. (1990). Role of calcium ions in regulation of mammalian intramitochondrial metabolism. Physiol. Rev. 70, 391-425.
159. McGeer, P. L., Itagaki, S., Akiyama, H., and McGeer, E. G. (1988). Rate of cell death in parkinsonism indicates active neuropathological process. Ann. Neurol. 24, 574-576.
160. McGeer, P. L., and McGeer, E. G. (2004). Inflammation and the degenerative diseases of aging. Ann. N. Y. Acad. Sci. 1035, 104-116.
161. McGeer, P. L., McGeer, E. G., and Suzuki, J. S. (1977). Aging and extrapyramidal function. Arch. Neurol. 34, 33-35.
162. McGeer, P. L., Schwab, C., Parent, A., and Doudet, D. (2003). Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration. Ann. Neurol. 54, 599-604.
163. McNaught, K. S., Belizaire, R., Isacson, O., Jenner, P., and Olanow, C. W. (2003). Altered proteasomal function in sporadic Parkinson's disease. Exp. Neurol. 179, 38-46.
164. McNaught, K. S., Belizaire, R., Jenner, P., Olanow, C. W., and Isacson, O. (2002a). Selective loss of 20S proteasome alpha-subunits in the substantia nigra pars compacta in Parkinson's disease. Neurosci. Lett. 326, 155-158.
165. McNaught, K. S., Jnobaptiste, R., Jackson, T., and Jengelley, T. A. (2010). The pattern of neuronal loss and survival may reflect differential expression of proteasome activators in Parkinson's disease. Synapse 64, 241-250.
166. McNaught, K. S., Olanow, C. W., Halliwell, B., Isacson, O., and Jenner, P. (2001). Failure of the ubiquitin-proteasome system in Parkinson's disease. Nat. Rev. Neurosci. 2, 589-594.
167. McNaught, K. S., Shashidharan, P., Perl, D. P., Jenner, P., and Olanow, C. W. (2002b). Aggresome-related biogenesis of Lewy bodies. Eur. J. Neurosci. 16, 2136-2148.
168. McRitchie, D. A., and Halliday, G. M. (1995). Calbindin D28k-containing neurons are restricted to the medial substantia nigra in humans. Neuroscience 65, 87-91.
169. McRitchie, D. A., Hardman, C. D., and Halliday, G. M. (1996). Cytoarchitectural distribution of calcium binding proteins in midbrain dopaminergic regions of rats and humans. J. Comp. Neurol. 364, 121-150.
170. Miller, G. W. (2007). Paraquat: the red herring of Parkinson's disease research. Toxicol. Sci. 100, 1-2.
171. Miller, G. W., Gainetdinov, R. R., Levey, A. I., and Caron, M. G. (1999). Dopamine transporters and neuronal injury. Trends Pharmacol. Sci. 20, 424-429.
172. Missale, C., Castelletti, L., Govoni, S., Spano, P. F., Trabucchi, M., and Hanbauer, I. (1985). Dopamine uptake is differentially regulated in rat striatum and nucleus accumbens. J. Neurochem. 45, 51-56.
173. Miyazaki, I., and Asanuma, M. (2009). Approaches to prevent dopamine quinone-induced neurotoxicity. Neurochem. Res. 34, 698-706.
174. Mizuno, Y., Sone, N., Suzuki, K., and Saitoh, T. (1988). Studies on the toxicity of 1-methyl-4-phenylpyridinium ion (MPP+) against mitochondria of mouse brain. J. Neurol. Sci. 86, 97-110.
175. Mogi, M., Harada, M., Kondo, T., Riederer, P., Inagaki, H., Minami, M., and Nagatsu, T. (1994a). Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci. Lett. 180, 147-150.
176. Mogi, M., Harada, M., Riederer, P., Narabayashi, H., Fujita, K., and Nagatsu, T. (1994b). Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci. Lett. 165, 208-210.
177. Mogi, M., Togari, A., Kondo, T., Mizuno, Y., Komure, O., Kuno, S., Ichinose, H., and Nagatsu, T. (2000). Caspase activities and tumor necrosis factor receptor R1 (p55) level are elevated in the substantia nigra from parkinsonian brain. J. Neural. Transm. 107, 335-341.
178. Muñoz, A., Rey, P., Guerra, M. J., Mendez-Alvarez, E., Soto-Otero, R., and Labandeira-Garcia, J. L. (2006). Reduction of dopaminergic degeneration and oxidative stress by inhibition of angiotensin converting enzyme in a MPTP model of parkinsonism. Neuropharmacology 51, 112-120.
179. Murakami, T., Shoji, M., Imai, Y., Inoue, H., Kawarabayashi, T., Matsubara, E., Harigaya, Y., Sasaki, A., Takahashi, R., and Abe, K. (2004). Pael-R is accumulated in Lewy bodies of Parkinson's disease. Ann. Neurol. 55, 439-442.
180. Nicklas, W. J., Vyas, I., and Heikkila, R. E. (1985). Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci. 36, 2503-2508.
181. Nishikawa, K., Li, H., Kawamura, R., Osaka, H., Wang, Y. L., Hara, Y., Hirokawa, T., Manago, Y., Amano, T., Noda, M., Aoki, S., and Wada, K. (2003). Alterations of structure and hydrolase activity of parkinsonism-associated human ubiquitin carboxyl-terminal hydrolase L1 variants. Biochem. Biophys. Res. Commun. 304, 176-183.
182. Novelli, A., Reilly, J. A., Lysko, P. G., and Henneberry, R. C. (1988). Glutamate becomes neurotoxic via the N-methyl-d-aspartate receptor when intracellular energy levels are reduced. Brain Res. 451, 205-212.
183. Nussbaum, R. L., and Ellis, C. E. (2003). Alzheimer's disease and Parkinson's disease. N. Engl. J. Med. 348, 1356-1364.
184. Olanow, C. W., and McNaught, K. S. (2006). Ubiquitin-proteasome system and Parkinson's disease. Mov. Disord. 21, 1806-1823.
185. Olzmann, J. A., Brown, K., Wilkinson, K. D., Rees, H. D., Huai, Q., Ke, H., Levey, A. I., Li, L., and Chin, L. S. (2004). Familial Parkinson's diseaseassociated L166P mutation disrupts DJ-1 protein folding and function. J. Biol. Chem. 279, 8506-8515.
186. Omelchenko, N., and Sesack, S. R. (2005). Laterodorsal tegmental projections to identified cell populations in the rat ventral tegmental area. J. Comp. Neurol. 483, 217-235.
187. Paisan-Ruiz, C., Jain, S., Evans, E. W., Gilks, W. P., Simon, J., van der Brug, M., Lopez de Munain, A., Aparicio, S., Gil, A. M., Khan, N., Johnson, J., Martinez, J. R., Nicholl, D., Carrera, I. M., Pena, A. S., de Silva, R., Lees, A., Marti-Masso, J. F., Perez-Tur, J., Wood, N. W., and Singleton, A. B. (2004). Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44, 595-600.
188. Pakkenberg, H., Andersen, B. B., Burns, R. S., and Pakkenberg, B. (1995). A stereological study of substantia nigra in young and old rhesus monkeys. Brain Res. 693, 201-206.
189. Palacino, J. J., Sagi, D., Goldberg, M. S., Krauss, S., Motz, C., Wacker, M., Klose, J., and Shen, J. (2004). Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J. Biol. Chem. 279, 18614-18622.
190. Pan, T., Kondo, S., Le, W., and Jankovic, J. (2008). The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease. Brain 131, 1969-1978.
191. Parker, W. D. Jr., Parks, J. K., and Swerdlow, R. H. (2008). Complex I deficiency in Parkinson's disease frontal cortex. Brain Res. 1189, 215-218.
192. Paschen, W., and Mengesdorf, T. (2005). Endoplasmic reticulum stress response and neurodegeneration. Cell Calcium 38, 409-415.
193. Pearce, R. K., Hawkes, C. H., and Daniel, S. E. (1995). The anterior olfactory nucleus in Parkinson's disease. Mov. Disord. 10, 283-287.
194. Pickart, C. M. (2004). Back to the future with ubiquitin. Cell 116, 181-190.
195. Plaitakis, A., and Shashidharan, P. (2000). Glutamate transport and metabolism in dopaminergic neurons of substantia nigra: implications for the pathogenesis of Parkinson's disease. J. Neurol. 247 (Suppl. 2), II25-II35.
196. Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., Stenroos, E. S., Chandrasekharappa, S., Athanassiadou, A., Papapetropoulos, T., Johnson, W. G., Lazzarini, A. M., Duvoisin, R. C., Di Iorio, G., Golbe, L. I., and Nussbaum, R. L. (1997). Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276, 2045-2047.
197. Poon, H. F., Frasier, M., Shreve, N., Calabrese, V., Wolozin, B., and Butterfield, D. A. (2005). Mitochondrial associated metabolic proteins are selectively oxidized in A30P alpha-synuclein transgenic mice--a model of familial Parkinson's disease. Neurobiol. Dis. 18, 492-498.
198. Pridgeon, J. W., Olzmann, J. A., Chin, L. S., and Li, L. (2007). PINK1 protects against oxidative stress by phosphorylating mitochondrial chaperone TRAP1. PLoS Biol. 5, e172. doi: 10.1371/journal.pbio.0050172.
199. Przedborski, S., and Jackson-Lewis, V. (1998). Mechanisms of MPTP toxicity. Mov. Disord. 13 (Suppl. 1), 35-38.
200. Ramirez, A., Heimbach, A., Grundemann, J., Stiller, B., Hampshire, D., Cid, L. P., Goebel, I., Mubaidin, A. F., Wriekat, A. L., Roeper, J., Al-Din, A., Hillmer, A. M., Karsak, M., Liss, B., Woods, C. G., Behrens, M. I., and Kubisch, C. (2006). Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat. Genet. 38, 1184-1191.
201. 2+: molecular determinants and functional consequences. Physiol. Rev. 86, 369-408.
202. Rochet, J. C., Outeiro, T. F., Conway, K. A., Ding, T. T., Volles, M. J., Lashuel, H. A., Bieganski, R. M., Lindquist, S. L., and Lansbury, P. T. (2004). Interactions among alpha-synuclein, dopamine, and biomembranes: some clues for understanding neurodegeneration in Parkinson's disease. J. Mol. Neurosci. 23, 23-34.
203. Rodriguez, M., Barroso-Chinea, P., Abdala, P., Obeso, J., and Gonzalez-Hernandez, T. (2001). Dopamine cell degeneration induced by intraventricular administration of 6-hydroxydopamine in the rat: similarities with cell loss in parkinson's disease. Exp. Neurol. 169, 163-181.
204. Rodriguez-Pallares, J., Rey, P., Parga, J. A., Muñoz, A., Guerra, M. J., and Labandeira-Garcia, J. L. (2008).Brain angiotensin enhances dopaminergic cell death via microglial activation and NADPH-derived ROS. Neurobiol. Dis. 31, 58-73.
205. Saito, Y., Ruberu, N. N., Sawabe, M., Arai, T., Kazama, H., Hosoi, T., Yamanouchi, H., and Murayama, S. (2004). Lewy body-related alpha-synucleinopathy in aging. J. Neuropathol. Exp. Neurol. 63, 742-749.
206. Salazar, M., Sokoloski, T. D., and Patil, P. N. (1978). Binding of dopaminergic drugs by the neuromelanin of the substantia nigra, synthetic melanins and melanin granules. Fed. Proc. 37, 2403-2407.
207. Sanchez-Ferrer, A., Rodriguez-Lopez, J. N., Garcia-Canovas, F., and Garcia-Carmona, F. (1995). Tyrosinase: a comprehensive review of its mechanism. Biochim. Biophys. Acta. 1247, 1-11.
208. Schapira, A. H. (2008). Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Lancet Neurol. 7, 97-109.
209. Schapira, A. H., Cooper, J. M., Dexter, D., Clark, J. B., Jenner, P., and Marsden, C. D. (1990). Mitochondrial complex I deficiency in Parkinson's disease. J. Neurochem. 54, 823-827.
210. Schon, E. A., and Manfredi, G. (2003). Neuronal degeneration and mitochondrial dysfunction. J. Clin. Invest. 111, 303-312.
211. Schuler, F., and Casida, J. E. (2001). The insecticide target in the PSST subunit of complex I. Pest. Manag. Sci. 57, 932-940.
212. Schultz, W. (2002). Getting formal with dopamine and reward. Neuron 36, 241-263.
213. Semchuk, K. M., Love, E. J., and Lee, R. G. (1992). Parkinson's disease and exposure to agricultural work and pesticide chemicals. Neurology 42, 1328-1335.
214. Shah, I. M., and Di Napoli, M. (2007). The ubiquitin-proteasome system and proteasome inhibitors in central nervous system diseases. Cardiovasc. Hematol. Disord. Drug Targets 7, 250-273.
215. Shendelman, S., Jonason, A., Martinat, C., Leete, T., and Abeliovich, A. (2004). DJ-1 is a redox-dependent molecular chaperone that inhibits alphasynuclein aggregate formation. PLoS Biol. 2, e362. doi: 10.1371/journal. pone.0001884.
216. Sherer, T. B., Kim, J. H., Betarbet, R., and Greenamyre, J. T. (2003). Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Exp. Neurol. 179, 9-16.
217. Shima, T., Sarna, T., Swartz, H. M., Stroppolo, A., Gerbasi, R., and Zecca, L. (1997). Binding of iron to neuromelanin of human substantia nigra and synthetic melanin: an electron paramagnetic resonance spetroscopy study. Free Radic. Biol. Med. 23, 110-119.
218. Shimada, S., Kitayama, S., Walther, D., and Uhl, G. (1992). Dopamine transporter mRNA: dense expression in ventral midbrain neurons. Brain Res. Mol. Brain Res. 13, 359-362.
219. Shimura, H., Hattori, N., Kubo, S., Yoshikawa, M., Kitada, T., Matsumine, H., Asakawa, S., Minoshima, S., Yamamura, Y., Shimizu, N., and Mizuno, Y. (1999). Immunohistochemical and subcellular localization of Parkin protein: absence of protein in autosomal recessive juvenile parkinsonism patients. Ann. Neurol. 45, 668-672.
220. Silvestri, L., Caputo, V., Bellacchio, E., Atorino, L., Dallapiccola, B., Valente, E. M., and Casari, G. (2005). Mitochondrial import and enzymatic activity of PINK1 mutants associated to recessive parkinsonism. Hum. Mol. Genet. 14, 3477-3492.
221. Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., Lincoln, S., Crawley, A., Hanson, M., Maraganore, D., Adler, C., Cookson, M. R., Muenter, M., Baptista, M., Miller, D., Blancato, J., Hardy, J., and Gwinn-Hardy, K. (2003). alpha-Synuclein locus triplication causes Parkinson's disease. Science 302, 841.
222. Snyder, H., Mensah, K., Theisler, C., Lee, J., Matouschek, A., and Wolozin, B. (2003). Aggregated and monomeric alpha-synuclein bind to the S6' proteasomal protein and inhibit proteasomal function. J. Biol. Chem. 278, 11753-11759.
223. Squier, T. C. (2001). Oxidative stress and protein aggregation during biological aging. Exp. Gerontol. 36, 1539-1550.
224. Stefanis, L., Larsen, K. E., Rideout, H. J., Sulzer, D., and Greene, L. A. (2001). Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. J. Neurosci. 21, 9549-9560.
225. 2+ channel isoforms for brain function. Biochem. Soc. Trans. 34, 903-909.
226. Sulzer, D., Bogulavsky, J., Larsen, K. E., Behr, G., Karatekin, E., Kleinman, M. H., Turro, N., Krantz, D., Edwards, R. H., Greene, L. A., and Zecca, L. (2000). Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles. Proc. Natl. Acad. Sci. U.S.A. 97, 11869-11874.
227. Sulzer, D., and Schmitz, Y. (2007). Parkinson's disease: return of an old prime suspect. Neuron 55, 8-10.
228. Surmeier, D. J. (2007). Calcium, ageing, and neuronal vulnerability in Parkinson's disease. Lancet Neurol. 6, 933-938.
229. Swartz, H. M., Sarna, T., and Zecca, L. (1992). Modulation by neuromelanin of the availability and reactivity of metal ions. Ann. Neurobiol. 32 Suppl. S69-S75.
230. Swerdlow, R. H., Parks, J. K., Miller, S. W., Tuttle, J. B., Trimmer, P. A., Sheehan, J. P., Bennett, J. P. Jr., Davis, R. E., and Parker, W. D. Jr. (1996). Origin and functional consequences of the complex I defect in Parkinson's disease. Ann. Neurol. 40, 663-671.
231. Taira, T., Saito, Y., Niki, T., Iguchi-Ariga, S. M., Takahashi, K., and Ariga, H. (2004). DJ-1 has a role in antioxidative stress to prevent cell death. EMBO Rep. 5, 213-218.
232. Takahashi, K., Taira, T., Niki, T., Seino, C., Iguchi-Ariga, S. M., and Ariga, H. (2001). DJ-1 positively regulates the androgen receptor by impairing the binding of PIASx alpha to the receptor. J. Biol. Chem. 276, 37556-37563.
233. Takahashi, N., Miner, L. L., Sora, I., Ujike, H., Revay, R. S., Kostic, V., Jackson-Lewis, V., Przedborski, S., and Uhl, G. R. (1997). VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. Proc. Natl. Acad. Sci. U.S.A. 94, 9938-9943.
234. Tanaka, Y., Engelender, S., Igarashi, S., Rao, R. K., Wanner, T., Tanzi, R. E., Sawa, A.V.L. D., Dawson, T. M., and Ross, C. A. (2001). Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Hum. Mol. Genet. 10, 919-926.
235. Taylor, T. N., Caudle, W. M., Shepherd, K. R., Noorian, A., Jackson, C. R., Iuvone, P. M., Weinshenker, D., Greene, J. G., and Miller, G. W. (2009). Nonmotor symptoms of Parkinson's disease revealed in an animal model with reduced monoamine storage capacity. J. Neurosci. 29, 8103-8113.
236. Thannickal, T. C., Lai, Y. Y., and Siegel, J. M. (2007).Hypocretin (orexin) cell loss in Parkinson's disease. Brain 130, 1586-1595.
237. Turski, W. A., and Lachowicz, L. (1991). The possibility of participation of different protein kinases in the regulation of degradation of Glp6[125I] Tyr8SP6-11 with different endopeptidases in subcellular fractions of rat brain. Int. J. Biochem. 23, 317-321.
238. Uhl, G. R., Walther, D., Mash, D., Faucheux, B., and Javoy-Agid, F. (1994). Dopamine transporter messenger RNA in Parkinson's disease and control substantia nigra neurons. Ann. Neurol. 35, 494-498.
239. Valente, E. M., Salvi, S., Ialongo, T., Marongiu, R., Elia, A. E., Caputo, V., Romito, L., Albanese, A., Dallapiccola, B., and Bentivoglio, A. R. (2004). PINK1 mutations are associated with sporadic early-onset parkinsonism. Ann. Neurol. 56, 336-341.
240. Varastet, M., Riche, D., Maziere, M., and Hantraye, P. (1994). Chronic MPTP treatment reproduces in baboons the differential vulnerability of mesencephalic dopaminergic neurons observed in Parkinson's disease. Neuroscience 63, 47-56.
241. Victorof, J., Zarow, C., Mack, W. J., Hsu, E., and Chui, H. C. (1996). Physical aggression is associated with preservation of substantia nigra pars compacta in Alzheimer disease. Arch. Neurol. 53, 428-434.
242. Wickens, J. R., Reynolds, J. N., and Hyland, B. I. (2003). Neural mechanisms of reward-related motor learning. Curr. Opin. Neurobiol. 13, 685-690.
243. Wilms, H., Rosenstiel, P., Romero-Ramos, M., Arlt, A., Schafer, H., Seegert, D., Kahle, P. J., Odoy, S., Claasen, J. H., Holzknecht, C., Brandenburg, L. O., Deuschl, G., Schreiber, S., Kirik, D., and Lucius, R. (2009). Suppression of MAP kinases inhibits microglial activation and attenuates neuronal cell death induced by alpha-synuclein protofibrils. Int. J. Immunopathol. Pharmacol. 22, 897-909.
244. Wilms, H., Rosenstiel, P., Sievers, J., Deuschl, G., Zecca, L., and Lucius, R. (2003). Activation of microglia by human neuromelanin is NF-kappaB dependent and involves p38 mitogen-activated protein kinase: implications for Parkinson's disease. FASEB J. 17, 500-502.
245. Wood-Kaczmar, A., Gandhi, S., Yao, Z., Abramov, A. Y., Miljan, E. A., Keen, G., Stanyer, L., Hargreaves, I., Klupsch, K., Deas, E., Downward, J., Mansfield, L., Jat, P., Taylor, J., Heales, S., Duchen, M. R., Latchman, D., Tabrizi, S. J., and Wood, N. W. (2008). PINK1 is necessary for long term survival and mitochondrial function in human dopaminergic neurons. PLoS One 3, e2455. doi: 10.1371/journal. pone.0002455.
246. Xue, C. J., Ng, J. P., Li, Y., and Wolf, M. E. (1996). Acute and repeated systemic amphetamine administration: effects on extracellular glutamate, aspartate, and serine levels in rat ventral tegmental area and nucleus accumbens. J. Neurochem. 67, 352-363.
247. Yamada, T., McGeer, P. L., Baimbridge, K. G., and McGeer, E. G. (1990). Relative sparing in Parkinson's disease of substantia nigra dopamine neurons containing calbindin-D28K. Brain Res. 526, 303-307.
248. Zafar, S. K., Siegel, D., and Ross, D. (2006). A potential role for cyclized quinines derived from dopamine, DOPA, and 3, 4-dihydroxyphenylacetic acid in proteasomal inhibition. Mol. Pharmacol. 70, 1079-1086.
249. Zarow, C., Lyness, S. A., Mortimer, J. A., and Chui, H. C. (2003). Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch. Neurol. 60, 337-341.
250. Zeevalk, G. D., Bernard, L. P., and Nicklas, W. J. (1998). Role of oxidative stress and the glutathione system in loss of dopamine neurons due to impairment of energy metabolism. J. Neurochem. 70, 1421-1430.
251. Zecca, L., Zucca, F. A., Wilms, H., and Sulzer, D. (2003). Neuromelanin of the substantia niga: a neuronal black hole with protective and toxic characteristics. Trends Neurosci. 26, 578-580.
252. Zhang, L., Shimoji, M., Thomas, B., Moore, D. J., Yu, S. W., Marupudi, N. I., Torp, R., Torgner, I. A., Ottersen, O. P., Dawson, T. M., and Dawson, V. L. (2005). Mitochondrial localization of the Parkinson's disease related protein DJ-1: implications for pathogenesis. Hum. Mol. Genet. 14, 2063-2073.
253. Zhang, Y., Gao, J., Chung, K. K., Huang, H., Dawson, V. L., and Dawson, T. M. (2000). Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc. Natl. Acad. Sci. U.S.A. 97, 13354-13359.